Published: 2020-09-10

In-Depth Reviews

Resident Competition Research Articles

The Impact of Skin Disease on Quality of Life in Rural Communities of Ghana

Caroline W Laggis, Aaron M Secrest, Martin Agyei, Sam Simister, Andrea N Davis, Ty Dickerson, Jamie LW Rhoads
| DOI https://doi.org/10.25251/skin.4.5.4

Page 417-423

Sentinel Lymph Node Predictors in Melanoma of Breslow Thickness 0.8-1.0 mm

Luisa Fernanda Christensen, David Carr, Sheena Hill, Elizabeth Ramser, Jaime Abraham Perez, Jeremy Bordeaux
| DOI https://doi.org/10.25251/skin.4.5.6

Page 431-437

COVID Concepts

Chilblains-Like Lesions as a Presenting Manifestation of COVID-19

Victoria Comeau, Marcus Goodman, Carmen Julian, Francesca M Ceci
| DOI https://doi.org/10.25251/skin.4.5.8

Page 440-442

Brief Articles

Cetuximab Induced Hidrocystomas: A Case Report

Nicole Nagrani, David E Castillo, Mariya Miteva, Anna Nichols
| DOI https://doi.org/10.25251/skin.4.5.9

Page 443-445

Eruptive Oral Mucoceles in a Neonate

Ghassan Niaz, Ellen H de Moll, Lauren Zinns, Bryan Tassavor, Robert G Phelps
| DOI https://doi.org/10.25251/skin.4.5.10

Page 446-448

Blistering Rash over Broken Ribs

Kathleen R Graham, Bethany R Rohr, Victor J Marks
| DOI https://doi.org/10.25251/skin.4.5.11

Page 449-451

A Rare Case of Angiolymphoid Hyperplasia without Eosinophils, with Review of the Literature

James Ko, Zachary P Nahmias, Patrick S Phelan, Sabra Abner, Kara Blackwell, Andras Schaffer
| DOI https://doi.org/10.25251/skin.4.5.15

Page 464-467

Short Communications

Compelling Comments

Commentary & Notes

Dermatologic History

2020 PANP Fall Clinical Conference® Posters: Psoriasis

An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis

Bruce Strober, Alice Gottlieb, Diamant Thaçi, Luis Puig, Matthew J Colombo, Sundeep Kundu, Renata Kisa, Subhashis Banerjee
| DOI https://doi.org/10.25251/skin.4.supp.27

Page s27

BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients

Kenneth Gordon, Kim Papp, Melinda Gooderham, Akimichi Morita, Peter Foley, Diamant Thaçi, Sundeep Kundu, Renata Kisa, Lan Wei, Subhashis Banergee
| DOI https://doi.org/10.25251/skin.4.supp.28

Page s28

Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2

Richard G Langley, Jeffrey Crowley, Melinda Gooderham, Kim A Papp, Neil J Korman, Lynda Spelman, Atsuyuki Igarashi, Mamitaro Ohtsuki, Aditya K Gupta, Paul Yamauchi, Jeffrey Parno, Alan M Mendelsohn, Stephen J Rozzo, Kimberly Eads
| DOI https://doi.org/10.25251/skin.4.supp.39

Page s39

Early and Maintained Response Levels in Psoriasis Patients Treated with Tildrakizumab

Kim A Papp, Jensen Yeung, Neil Shear, Lorne Albrecht, Charles Lynde, Jingchuan Zhang, Yang Zhao, Jeff Parno, Alan M Mendelsohn, Melinda Gooderham
| DOI https://doi.org/10.25251/skin.4.supp.41

Page s41

Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

K Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Thaçi, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich
| DOI https://doi.org/10.25251/skin.4.supp.44

Page s44

Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies

A Blauvelt, C Paul, P van de Kerkhof, R B Warren, A B Gottlieb, R G Langley, F Brock, C Arendt, M Boehnlein, M Lebwohl, K Reich
| DOI https://doi.org/10.25251/skin.4.supp.46

Page s46

Atopic Dermatitis

Acne & Rosacea

Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials

Angela Moore, Suzanne Bruce, Neil Sadick, Eduardo Tschen, Philip Werschler, Sunil Dhawan, Douglas Farsha, Michael Gold, Scott Guenthner, Steve Kempers, Leon Kircik, Jennifer Parish, Marta Rendon, Phoebe Rich, Linda Stein-Gold, Stephen Tyring, Robert Weiss, Adnan Nasir, Carsten Schmitz, Terry Boodhoo, Alexandre Kaoukhov, David Berk, Fran Cook-Bolden, Ayman Grada
| DOI https://doi.org/10.25251/skin.4.supp.51

Page s52

Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris

David M Pariser, Lawrence J Green, Edward L Lain, Carsten Schmitz, Amy S Chinigo, Brian McNames, David R Berk, Jamison Hoffman, Ayman Grada
| DOI https://doi.org/10.25251/skin.4.supp.52

Page s53

Trifarotene 50 µg/G Cream for Treatment of Acne Vulgaris – A Summary of Two Randomized Trials and a Long-Term Safety Study

Jerry Tan, James Del Rosso, Jonathan Weiss, Linda Stein Gold, Fran Cook-Bolden, Lawrence Eichenfeld, Emil Tanghetti, Alessandra Alió Saenz, Faiz Ahmad
| DOI https://doi.org/10.25251/skin.4.supp.56

Page s57

Nail Unit Disorders

Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients

Lawrence F Eichenfield, Boni Elewski, Jeffrey L Sugarman, Ted Rosen, Aditya Gupta, Wendy Cantrell, Radhakrishnan Pillai, Abby Jacobson
| DOI https://doi.org/10.25251/skin.4.supp.60

Page s61

Dermatopharmacology

Skin Cancer